Literature DB >> 826157

Incidence, technique of isolation, and treatment of group B streptococci in obstetric patients.

J S Gordon, A J Sbarra.   

Abstract

A prospective study was performed to determine the incidence of group B streptococci cultured from the cervix in a series of obstetric clinic patients at St. Margaret's Hospital. Cultures were taken during each trimester and planted to both a blood agar plate and a selective broth medium. Of a total of 812 cultures, 18 were positive, an over-all incidence of 2.2 per cent. During the first, second, and third trimesters, 2.2 per cent, 2.5 per cent, and 1.9 per cent of cultures were positive, respectively. Women with positive cultures were treated with a 10 day course of oral penicillin or a suitable alternative; four of 16 had persistent positive cultures at the end of the first treatment period, three of these four responded to a second course of antibiotics, and the remaining patient responded after a third treatment course. The total number of positive cultures by selective broth was 24, compared to nine in blood agar, indicating a 2.7-fold increase in pickup by the selective broth.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 826157     DOI: 10.1016/0002-9378(76)90695-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  Group B beta-hemolytic streptococci analysis of 242 isolations.

Authors:  C C Sampson; E Stotts
Journal:  J Natl Med Assoc       Date:  1977-07       Impact factor: 1.798

2.  Risk factors in early-onset neonatal group b streptococcal infections.

Authors:  P B Stewardson-Krieger; S P Gotoff
Journal:  Infection       Date:  1978       Impact factor: 3.553

3.  Group B streptococcal vertebral osteomyelitis in an adult.

Authors:  G Elhanan; R Raz
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

Review 4.  Epidemiology of group B streptococcal disease in the United States: shifting paradigms.

Authors:  A Schuchat
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.